Premium
Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome‐associated febrile crisis
Author(s) -
Cailliez M.,
Garaix F.,
RoussetRouvière C.,
Bruno D.,
KonePaut I.,
Sarles J.,
Chabrol B.,
Tsimaratos M.
Publication year - 2006
Publication title -
journal of inherited metabolic disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.462
H-Index - 102
eISSN - 1573-2665
pISSN - 0141-8955
DOI - 10.1007/s10545-006-0408-7
Subject(s) - anakinra , medicine , immunoglobulin d , vaccination , immunology , pediatrics , intensive care medicine , disease , antibody , b cell
Summary Hyper‐IgD and periodic fever syndrome (HIDS) is a hereditary autoinflammatory syndrome, characterized by recurrent inflammatory attacks. Treatment of HIDS is difficult. Recently, the IL‐1ra analogue anakinra was reported to be successful in aborting the IgD inflammatory attacks in a vaccination model. We report a clinical case of spectacular reduction of febrile attacks in a severe HIDS patient.